Teva Pharmaceutical Industries (TEVA) Equity Average: 2016-2025
Historic Equity Average for Teva Pharmaceutical Industries (TEVA) over the last 9 years, with Sep 2025 value amounting to $7.0 billion.
- Teva Pharmaceutical Industries' Equity Average rose 8.82% to $7.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 billion, marking a year-over-year increase of 8.82%. This contributed to the annual value of $6.8 billion for FY2024, which is 19.24% down from last year.
- Teva Pharmaceutical Industries' Equity Average amounted to $7.0 billion in Q3 2025, which was up 7.52% from $6.6 billion recorded in Q2 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Equity Average ranged from a high of $11.4 billion in Q3 2021 and a low of $5.8 billion during Q1 2025.
- Moreover, its 3-year median value for Equity Average was $7.1 billion (2024), whereas its average is $7.1 billion.
- As far as peak fluctuations go, Teva Pharmaceutical Industries' Equity Average declined by 25.68% in 2021, and later grew by 8.82% in 2025.
- Teva Pharmaceutical Industries' Equity Average (Quarterly) stood at $11.3 billion in 2021, then declined by 20.23% to $9.1 billion in 2022, then dropped by 14.31% to $7.8 billion in 2023, then fell by 24.17% to $5.9 billion in 2024, then climbed by 8.82% to $7.0 billion in 2025.
- Its last three reported values are $7.0 billion in Q3 2025, $6.6 billion for Q2 2025, and $5.8 billion during Q1 2025.